Search for content, post, videos

Oncopeptides announces leadership changes

Marty Duvall and Jakob Lindberg

The Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO, and Jakob Lindberg assumes the role as Chief Scientific Officer, CSO.

Jakob Lindberg has been CEO since the restart of the company in 2011. He assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who has held the position as CSO since 2018. Christian will continue as a Senior Advisor.

“The submission of the New Drug Application to the FDA, which was announced earlier, marks an important inflection point for Oncopeptides. As we embark on the next phase of our journey, I am very happy to announce that Jakob will continue his dedicated scientific engagement in Oncopeptides as CSO and that we have been able to attract an industry leader like Marty as CEO in Oncopeptides,” says Per Wold-Olsen, Chairman of Oncopeptides. “Marty will lead the transformation of Oncopeptides into a fully-fledged integrated global biotech company, headquartered in Stockholm, Sweden.”

The next phase of the journey

Marty J Duvall brings global commercialization skills from executive leadership roles in pharma and biotech including experience from the oncology and hematology space. Most recently as the CEO of Tocagen Inc.

“I am excited to join Oncopeptides to lead the company through its next phase and engage in the commercialization of melflufen”, says Marty J Duvall, “I am impressed by Oncopeptides’ strong scientific platform and our compelling phase 2 data. With melflufen, I strongly believe that we have the potential to add significant value to patients with multiple myeloma who in many cases lack treatment options”.

These leadership changes will be effective as of 1 July  2020.

“I am thrilled to get the opportunity to dedicate my time to exploit the potential of our unique PDC-platform and drive the scientific agenda beyond melflufen,” says Jakob Lindberg, outgoing CEO of Oncopeptides. “Our technology platform is truly exciting; it enables us to broaden the indications and provide new drug candidates that will be instrumental for the long-term growth of Oncopeptides.”

Photo of Marty Duvall and Jakob Lindberg